Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 10:00 ET | Source: Therini Bio, Inc.

Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies
April 29, 2025 10:00 ET | Source: Therini Bio, Inc.

Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases

Therini Bio's novel approach to treating neurodegenerative diseases yielded positive results in a Phase 1a study evaluating its lead candidate, THN391.
May 08, 2024 09:00 ET | Source: Therini Bio, Inc.

Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases

THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
October 24, 2023 09:05 ET | Source: Therini Bio, Inc.

Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia

- THN391 was found to be safe and well-tolerated -- THN391 demonstrated a prolonged half-life and dose proportional Cmax levels -- The data will be presented October 25-27th at CTAD 2023 - ...